Publication in Pharmaceuticals in May 2022 is titled Augmented Efficacy of Uttroside-B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma
Read more at prnewswire.comQ BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
PR Newswire -
Tue Jul 26, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here